<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26705120</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>263</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myasthenia gravis: a clinical-immunological update.</ArticleTitle>
        <Pagination>
          <StartPage>826</StartPage>
          <EndPage>834</EndPage>
          <MedlinePgn>826-34</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-015-7963-5</ELocationID>
        <Abstract>
          <AbstractText>Myasthenia gravis (MG) is the archetypic disorder of both the neuromuscular junction and autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine receptors cause fatigable weakness of skeletal muscles. In the rest, a variable proportion possesses antibodies to muscle-specific tyrosine kinase while the remainder of seronegative MG is being explained through cell-based assays using a receptor-clustering technique and, to a lesser extent, proposed new antigenic targets. The incidence and prevalence of MG are increasing, particularly in the elderly. New treatments are being developed, and results from the randomised controlled trial of thymectomy in non-thymomatous MG, due for release in early 2016, will be of particular clinical value. To help navigate an evidence base of varying quality, practising clinicians may consult new MG guidelines in the fields of pregnancy, ocular and generalised MG (GMG). This review focuses on updates in epidemiology, immunology, therapeutic and clinical aspects of GMG in adults.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Binks</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vincent</LastName>
            <ForeName>Angela</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palace</LastName>
            <ForeName>Jacqueline</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK. jacqueline.palace@ndcn.ox.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cell-based assays</Keyword>
        <Keyword MajorTopicYN="N">IgG4</Keyword>
        <Keyword MajorTopicYN="N">LRP4</Keyword>
        <Keyword MajorTopicYN="N">MuSK</Keyword>
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Neuromuscular junction</Keyword>
        <Keyword MajorTopicYN="N">Thymectomy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26705120</ArticleId>
        <ArticleId IdType="pmc">PMC4826656</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-015-7963-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-015-7963-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–490. doi: 10.1016/S1474-4422(09)70063-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70063-8</ArticleId>
            <ArticleId IdType="pmc">PMC2730933</ArticleId>
            <ArticleId IdType="pubmed">19375665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoch W, McConville J, Helms S, et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–368. doi: 10.1038/85520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/85520</ArticleId>
            <ArticleId IdType="pubmed">11231638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McConville J, Farrugia ME, Beeson D, et al.  Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580–584. doi: 10.1002/ana.20061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20061</ArticleId>
            <ArticleId IdType="pubmed">15048899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koneczny I, Cossins J, Waters P, et al.  MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One. 2013;8(11):e80695. doi: 10.1371/journal.pone.0080695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0080695</ArticleId>
            <ArticleId IdType="pmc">PMC3820634</ArticleId>
            <ArticleId IdType="pubmed">24244707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huijbers MG, Zhang W, Klooster R, et al.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA. 2013;110(51):20783–20788. doi: 10.1073/pnas.1313944110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1313944110</ArticleId>
            <ArticleId IdType="pmc">PMC3870730</ArticleId>
            <ArticleId IdType="pubmed">24297891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Jacob S, Viegas S, et al.  IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008;131(Pt 7):1940–1952. doi: 10.1093/brain/awn092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn092</ArticleId>
            <ArticleId IdType="pmc">PMC2442426</ArticleId>
            <ArticleId IdType="pubmed">18515870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob S, Viegas S, Leite MI, et al.  Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol. 2012;69(8):994–1001. doi: 10.1001/archneurol.2012.437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2012.437</ArticleId>
            <ArticleId IdType="pubmed">22689047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez Cruz PM, Al-Hajjar M, Huda S, et al.  Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015;72(6):642–649. doi: 10.1001/jamaneurol.2015.0203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.0203</ArticleId>
            <ArticleId IdType="pmc">PMC6044422</ArticleId>
            <ArticleId IdType="pubmed">25894002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cossins J, Belaya K, Zoltowska K, et al.  The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci. 2012;1275:123–128. doi: 10.1111/j.1749-6632.2012.06833.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2012.06833.x</ArticleId>
            <ArticleId IdType="pubmed">23278587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carr AS, Cardwell CR, McCarron PO, et al.  A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;18(10):46. doi: 10.1186/1471-2377-10-46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-10-46</ArticleId>
            <ArticleId IdType="pmc">PMC2905354</ArticleId>
            <ArticleId IdType="pubmed">20565885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology. 2011;76(17):1526–1528. doi: 10.1212/WNL.0b013e318217e735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318217e735</ArticleId>
            <ArticleId IdType="pubmed">21519005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benatar M, Sanders DB, Burns TM, et al.  Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6):909–917. doi: 10.1002/mus.23330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23330</ArticleId>
            <ArticleId IdType="pubmed">22581550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benatar M, Sanders DB, Wolfe GI, et al.  Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci. 2012;1275:17–22. doi: 10.1111/j.1749-6632.2012.06780.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2012.06780.x</ArticleId>
            <ArticleId IdType="pubmed">23278573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clinical trials.gov. Efficacy of prednisone in the treatment of ocular myasthenia (EPITOME). ClinicalTrials.gov identifier NCT00995722 [on-line]. Web-page last updated 2015 Jan 6. https://clinicaltrials.gov/ct2/show/NCT00995722?term=EPITOME&amp;rank=1. Accessed 13 Aug 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Keung B, Robeson KR, DiCapua DB, et al.  Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry. 2013;84(12):1407–1409. doi: 10.1136/jnnp-2012-303664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2012-303664</ArticleId>
            <ArticleId IdType="pubmed">23761915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe GI, Kaminski HJ, Jaretzki A, et al.  Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci. 2003;998:473–480. doi: 10.1196/annals.1254.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1254.061</ArticleId>
            <ArticleId IdType="pubmed">14592916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(1):7–15. doi: 10.1212/WNL.55.1.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.1.7</ArticleId>
            <ArticleId IdType="pubmed">10891896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cea G, Benatar M, Verdugo RJ et al (2013) Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 10:CD008111</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24122674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norwood F, Dhanjal M, Hill M, et al.  Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry. 2014;85(5):538–543. doi: 10.1136/jnnp-2013-305572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2013-305572</ArticleId>
            <ArticleId IdType="pubmed">23757420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerty E, Elsais A, Argov Z, et al.  EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687–693. doi: 10.1111/ene.12359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12359</ArticleId>
            <ArticleId IdType="pubmed">24471489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sussman J, Farrugia ME, Maddison P, et al.  Myasthenia gravis: association of British Neurologists’ management guidelines. Pract Neurol. 2015;15(3):199–206. doi: 10.1136/practneurol-2015-001126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/practneurol-2015-001126</ArticleId>
            <ArticleId IdType="pubmed">25977271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruz PMR, Palace J, Beeson D. Inherited disorders of the neuromuscular junction: an update. J Neurol. 2014;261(11):2234–2243. doi: 10.1007/s00415-014-7520-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-014-7520-7</ArticleId>
            <ArticleId IdType="pubmed">25305004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong SH, Huda S, Vincent A, et al.  Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep. 2014;14(1):421. doi: 10.1007/s11910-013-0421-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-013-0421-9</ArticleId>
            <ArticleId IdType="pubmed">24272275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47(5):1233–1238. doi: 10.1212/WNL.47.5.1233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.47.5.1233</ArticleId>
            <ArticleId IdType="pubmed">8909435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulas K, Tisbri E, Kokla A, et al.  Epidemiology of seropositive myasthenia gravis in Greece. J Neurol Neurosurg Psychiatry. 2001;71(3):352–356. doi: 10.1136/jnnp.71.3.352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.71.3.352</ArticleId>
            <ArticleId IdType="pmc">PMC1737536</ArticleId>
            <ArticleId IdType="pubmed">11511710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent A, Clover L, Buckley C, et al.  Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003;74(8):1105–1108. doi: 10.1136/jnnp.74.8.1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.74.8.1105</ArticleId>
            <ArticleId IdType="pmc">PMC1738592</ArticleId>
            <ArticleId IdType="pubmed">12876244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui N, Nakane S, Nakagawa Y, et al.  Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry. 2009;80(10):1168–1171. doi: 10.1136/jnnp.2008.152637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2008.152637</ArticleId>
            <ArticleId IdType="pubmed">19762910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murai H, Yamashita N, Watanabe M, et al.  Characteristics of myasthenia according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305(1–2):97–102. doi: 10.1016/j.jns.2011.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2011.03.004</ArticleId>
            <ArticleId IdType="pubmed">21440910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology. 2005;65(6):928–930. doi: 10.1212/01.wnl.0000176067.32186.a3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000176067.32186.a3</ArticleId>
            <ArticleId IdType="pubmed">16186537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parr JR, Andrew MJ, Finnis M, et al.  How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child. 2014;99(6):539–542. doi: 10.1136/archdischild-2013-304788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/archdischild-2013-304788</ArticleId>
            <ArticleId IdType="pubmed">24500997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alkhawajah N, Oger J. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve. 2013;48(5):705–710. doi: 10.1002/mus.23964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23964</ArticleId>
            <ArticleId IdType="pubmed">23893883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Meel RH, Lipka AF, van Zwet EW, et al.  Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. J Neuroimmunol. 2015;15(282):123–125. doi: 10.1016/j.jneuroim.2015.03.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2015.03.018</ArticleId>
            <ArticleId IdType="pubmed">25903739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Batocchi AP, Minisci C, et al.  Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc. 2000;48(11):1442–1448. doi: 10.1111/j.1532-5415.2000.tb02635.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1532-5415.2000.tb02635.x</ArticleId>
            <ArticleId IdType="pubmed">11083321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Živković SA, Clemens PR, Lacomis D. Characteristics of late-onset myasthenia gravis. J Neurol. 2012;259(10):2167–2171. doi: 10.1007/s00415-012-6478-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-012-6478-6</ArticleId>
            <ArticleId IdType="pubmed">22476514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Compston DA, Vincent A, Newsom-Davis J, et al.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103(3):579–601. doi: 10.1093/brain/103.3.579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/103.3.579</ArticleId>
            <ArticleId IdType="pubmed">6968236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5(2):133–139. doi: 10.1038/ni1033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1033</ArticleId>
            <ArticleId IdType="pubmed">14749784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Kawaguchi N, Kanai T, et al.  Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. J Neurol. 2015;262(4):1019–1023. doi: 10.1007/s00415-015-7673-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-7673-z</ArticleId>
            <ArticleId IdType="pubmed">25683765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchida M, Yamoto Y, Souma T, et al.  Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg. 1999;67(6):1563–1567. doi: 10.1016/S0003-4975(99)00167-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0003-4975(99)00167-8</ArticleId>
            <ArticleId IdType="pubmed">10391255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>UK clinical research network study portfolio. A prospective study of late-onset myasthenia gravis. UKCRN 13582 [on-line]. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13582. Accessed 13 Aug 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Phillips LH, Juel VC. Myasthenia gravis in the tenth decade. Muscle Nerve. 1999;22(9):1297–1298. doi: 10.1002/(SICI)1097-4598(199909)22:9&lt;1297::AID-MUS22&gt;3.0.CO;2-C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4598(199909)22:9&lt;1297::AID-MUS22&gt;3.0.CO;2-C</ArticleId>
            <ArticleId IdType="pubmed">10454731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alshekhlee A, Miles JD, Katirji B, et al.  Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72(18):1548–1554. doi: 10.1212/WNL.0b013e3181a41211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181a41211</ArticleId>
            <ArticleId IdType="pubmed">19414721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punga AR, Sawada M, Stalberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve. 2008;37(3):300–307. doi: 10.1002/mus.20935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20935</ArticleId>
            <ArticleId IdType="pubmed">18069667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, El-Salem K, Massey JM, et al.  Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978–1980. doi: 10.1212/01.WNL.0000065882.63904.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000065882.63904.53</ArticleId>
            <ArticleId IdType="pubmed">12821744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Tonali PA, Padua L, et al.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(Pt 10):2304–2311. doi: 10.1093/brain/awg223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg223</ArticleId>
            <ArticleId IdType="pubmed">12821509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40. doi: 10.1002/mus.22006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.22006</ArticleId>
            <ArticleId IdType="pubmed">21674519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavrnic D, Losen M, Vujic A, et al.  The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005;76(8):1099–1102. doi: 10.1136/jnnp.2004.052415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2004.052415</ArticleId>
            <ArticleId IdType="pmc">PMC1739764</ArticleId>
            <ArticleId IdType="pubmed">16024887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasnoor M, Wolfe GI, Nations S et al  Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience. Muscle Nerve. 2010;41(3):370–374. doi: 10.1002/mus.21533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.21533</ArticleId>
            <ArticleId IdType="pubmed">19882635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol. 2005;18(5):519–525. doi: 10.1097/01.wco.0000180660.57801.3f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.wco.0000180660.57801.3f</ArticleId>
            <ArticleId IdType="pubmed">16155434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh JH, Chen WH, Chiu HC, et al.  Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology. 2004;62(11):2131–2132. doi: 10.1212/01.WNL.0000128042.28877.C3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000128042.28877.C3</ArticleId>
            <ArticleId IdType="pubmed">15184635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsiamalos P, Kordas G, Kokla A, et al.  Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol. 2009;16(8):925–930. doi: 10.1111/j.1468-1331.2009.02624.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2009.02624.x</ArticleId>
            <ArticleId IdType="pubmed">19374661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry. 2007;78(4):417–418. doi: 10.1136/jnnp.2006.102517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.102517</ArticleId>
            <ArticleId IdType="pmc">PMC2077782</ArticleId>
            <ArticleId IdType="pubmed">17056627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niks EH, Kuks JB, Roep BO, et al.  Strong association of MuSK antibody–positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006;66(11):1772–1774. doi: 10.1212/01.wnl.0000218159.79769.5c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000218159.79769.5c</ArticleId>
            <ArticleId IdType="pubmed">16769963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartoccioni E, Scuderi F, Augugliaro et al (2009) HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72(2):195–197</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19139372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alahgholi-Hajibehzad M, Yilmaz V, Gülsen-Parman Y, et al.  Association of HLA-DRB*1, -DRB*16 and -DQB1*05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol. 2013;74(12):1633–1635. doi: 10.1016/j.humimm.2013.08.271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humimm.2013.08.271</ArticleId>
            <ArticleId IdType="pubmed">23993985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waters P, McKeon A, Leite MI, et al.  Serologic diagnosis of NMO. A multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665–671. doi: 10.1212/WNL.0b013e318248dec1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318248dec1</ArticleId>
            <ArticleId IdType="pmc">PMC3286228</ArticleId>
            <ArticleId IdType="pubmed">22302543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez Cruz PM, Huda S, López-Ruiz P, et al.  Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp Neurol. 2015;270:66–71. doi: 10.1016/j.expneurol.2015.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2015.01.011</ArticleId>
            <ArticleId IdType="pubmed">25783660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devic P, Petiot P, Simonet T, et al.  Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol. 2014;21(1):130–134. doi: 10.1111/ene.12270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12270</ArticleId>
            <ArticleId IdType="pubmed">24112557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsonis AI, Zisimopoulou P, Lazaridis K, et al.  MuSK autoantibodies in myasthenia gravis detected by cell based assay—a multinational study. J Neuroimmunol. 2015;15(284):10–17. doi: 10.1016/j.jneuroim.2015.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2015.04.015</ArticleId>
            <ArticleId IdType="pubmed">26025053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat. 2014;224(1):29–35. doi: 10.1111/joa.12034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joa.12034</ArticleId>
            <ArticleId IdType="pmc">PMC3867884</ArticleId>
            <ArticleId IdType="pubmed">23458718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim N, Steigler AL, Cameron TO, et al.  Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell. 2008;135(2):334–342. doi: 10.1016/j.cell.2008.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2008.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC2933840</ArticleId>
            <ArticleId IdType="pubmed">18848351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Luo S, Wang Q, et al.  LRP4 serves as a coreceptor of agrin. Neuron. 2008;60(2):285–297. doi: 10.1016/j.neuron.2008.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2008.10.006</ArticleId>
            <ArticleId IdType="pmc">PMC2743173</ArticleId>
            <ArticleId IdType="pubmed">18957220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huijbers MG, Querol LA, Niks EH, et al.  The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015;22(8):1151–1161. doi: 10.1111/ene.12758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12758</ArticleId>
            <ArticleId IdType="pubmed">26032110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartoccioni E, Scuderi F, Minicuci GM, et al.  Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology. 2006;67(3):505–507. doi: 10.1212/01.wnl.0000228225.23349.5d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000228225.23349.5d</ArticleId>
            <ArticleId IdType="pubmed">16894117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niks EH, van Leeuwen Y, Leite MI, et al.  Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008;195(1–2):151–156. doi: 10.1016/j.jneuroim.2008.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2008.01.013</ArticleId>
            <ArticleId IdType="pubmed">18384886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klooster R, Plomp JJ, Huijbers MG, et al.  Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012;135(Pt 4):1081–1101. doi: 10.1093/brain/aws025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws025</ArticleId>
            <ArticleId IdType="pubmed">22396395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viegas S, Jacobson L, Waters P, et al.  Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol. 2012;234(2):506–512. doi: 10.1016/j.expneurol.2012.01.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2012.01.025</ArticleId>
            <ArticleId IdType="pubmed">22326541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yumoto N, Kim N, Burden S. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature. 2012;489(7416):438–442. doi: 10.1038/nature11348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11348</ArticleId>
            <ArticleId IdType="pmc">PMC3448831</ArticleId>
            <ArticleId IdType="pubmed">22854782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi O, Hamuro J, Motomura M, et al.  Autoantibodies to low-density lipoprotein receptor–related protein 4 in Myasthenia Gravis. Ann Neurol. 2011;69(2):418–422. doi: 10.1002/ana.22312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22312</ArticleId>
            <ArticleId IdType="pubmed">21387385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pevzner A, Schoser B, Peters K, et al.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody negative myasthenia gravis. J Neurol. 2012;259(3):427–435. doi: 10.1007/s00415-011-6194-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-011-6194-7</ArticleId>
            <ArticleId IdType="pubmed">21814823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Tzartos JS, Belimezi M, et al.  Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445–451. doi: 10.1001/archneurol.2011.2393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.2393</ArticleId>
            <ArticleId IdType="pubmed">22158716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zisimopoulou P, Evangelakou P, Tzartos J, et al.  A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145. doi: 10.1016/j.jaut.2013.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2013.12.004</ArticleId>
            <ArticleId IdType="pubmed">24373505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Shen C, Bealmear B, et al.  Autoantibodies to agrin in myasthenia gravis patients. PLoS One. 2014;9(3):e91816. doi: 10.1371/journal.pone.0091816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0091816</ArticleId>
            <ArticleId IdType="pmc">PMC3954737</ArticleId>
            <ArticleId IdType="pubmed">24632822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasperi C, Melms A, Schoser B, et al.  Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82(22):1976–1983. doi: 10.1212/WNL.0000000000000478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000478</ArticleId>
            <ArticleId IdType="pubmed">24793185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cartaud A, Strochlic L, Guerra M, et al.  MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol. 2004;165(4):505–515. doi: 10.1083/jcb.200307164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200307164</ArticleId>
            <ArticleId IdType="pmc">PMC2172359</ArticleId>
            <ArticleId IdType="pubmed">15159418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katarzyna M, Belaya K, Leite M, et al.  Collagen Q—a potential target for autoantibodies in myasthenia gravis. J Neurol Sci. 2015;348(1–2):241–244. doi: 10.1016/j.jns.2014.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2014.12.015</ArticleId>
            <ArticleId IdType="pmc">PMC6044427</ArticleId>
            <ArticleId IdType="pubmed">25577314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Coutinho E, Lana-Peixoto M, et al.  Myasthenia gravis and neuromyelitis optica spectrum disorder. A multicenter study of 16 patients. Neurology. 2012;78(20):1601–1607. doi: 10.1212/WNL.0b013e31825644ff.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31825644ff</ArticleId>
            <ArticleId IdType="pmc">PMC3348852</ArticleId>
            <ArticleId IdType="pubmed">22551731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology. 2006;67(5):881–883. doi: 10.1212/01.wnl.0000234142.41728.a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000234142.41728.a0</ArticleId>
            <ArticleId IdType="pubmed">16966558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isbister CM, Mackenzie PJ, Anderson D. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler. 2003;9(6):550–553. doi: 10.1191/1352458503ms964oa.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1191/1352458503ms964oa</ArticleId>
            <ArticleId IdType="pubmed">14664466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spillane J, Christofi G, Sidle KC, et al.  Myasthenia gravis and neuromyelitis optica: a causal link. Mult Scler Relat Disord. 2013;2(3):233–237. doi: 10.1016/j.msard.2013.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2013.01.003</ArticleId>
            <ArticleId IdType="pubmed">25877729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bever CT, Aquino AV, Penn AS, et al.  Prognosis of ocular myasthenia. Ann Neurol. 1983;14(5):516–519. doi: 10.1002/ana.410140504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410140504</ArticleId>
            <ArticleId IdType="pubmed">6651238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer N, Sigg B, Melms A et al (1997) Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62(2):156–162</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC486727</ArticleId>
            <ArticleId IdType="pubmed">9048716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314–1320. doi: 10.1007/s00415-009-5120-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5120-8</ArticleId>
            <ArticleId IdType="pubmed">19377863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong SH, Plant GT, Cornblath W (2015) Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol [Epub ahead of print]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26218625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mee J, Paine M, Byrne E, et al.  Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23(4):251–255. doi: 10.1097/00041327-200312000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00041327-200312000-00002</ArticleId>
            <ArticleId IdType="pubmed">14663303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grob D, Brunner N, Namba T, et al.  Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149. doi: 10.1002/mus.20950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20950</ArticleId>
            <ArticleId IdType="pubmed">18059039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong S, Petrie A, Plant G (2015) Ocular MG: towards a risk of generalisation (‘ROG’) score. In: Association of British Neurologists (ABN) annual meeting, final programme and abstract book, 2015 May 20-2; Harrogate, UK: ABN; 2015 p 48</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep. 2011;11(1):89–96. doi: 10.1007/s11910-010-0151-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-010-0151-1</ArticleId>
            <ArticleId IdType="pubmed">20927659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Newsom-Davis J, Lecky B, et al.  A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778–1783. doi: 10.1212/WNL.50.6.1778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.50.6.1778</ArticleId>
            <ArticleId IdType="pubmed">9633727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heckmann J, Rawoot A, Bateman K, et al.  A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;5(11):97. doi: 10.1186/1471-2377-11-97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-11-97</ArticleId>
            <ArticleId IdType="pmc">PMC3170595</ArticleId>
            <ArticleId IdType="pubmed">21819556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, McConville J, Chaudhry V, et al.  Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004;30(1):55–60. doi: 10.1002/mus.20069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20069</ArticleId>
            <ArticleId IdType="pubmed">15221879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddison P, McConville J, Farrugia ME, et al.  The use of rituximab in myasthenia gravis and Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671–673. doi: 10.1136/jnnp.2009.197632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.197632</ArticleId>
            <ArticleId IdType="pubmed">20392977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Díaz-Manera J, Martínez-Hernández E, Querol L, et al.  Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193. doi: 10.1212/WNL.0b013e3182407982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182407982</ArticleId>
            <ArticleId IdType="pubmed">22218276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iorio R, Damato V, Aboini PE, et al.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262(5):1115–1119. doi: 10.1007/s00415-014-7532-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-014-7532-3</ArticleId>
            <ArticleId IdType="pubmed">25308632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catzola V, Battaglia A, Buzzonetti A, et al.  Changes in regulatory T-cells after rituximab in two patients with refractory myasthenia gravis. J Neurol. 2013;260(8):2163–2165. doi: 10.1007/s00415-013-6987-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-6987-y</ArticleId>
            <ArticleId IdType="pubmed">23749295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard JF, Barohn RJ, Cutter GR, et al.  A randomized, double-blind, placebo-controlled phase II trial of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84. doi: 10.1002/mus.23839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23839</ArticleId>
            <ArticleId IdType="pubmed">23512355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clinical trials.gov. Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN study). ClinicalTrials.gov identifier NCT01997229 [on-line]. Web-page last updated 2015 July 6. https://clinicaltrials.gov/ct2/show/NCT01997229. Accessed 13 Aug 2015</Citation>
        </Reference>
        <Reference>
          <Citation>Argov Z, McKee D, Agus S, et al.  Treatment of human myasthenia with oral antisense suppression of acetylcholinesterase. Neurology. 2007;69(7):699–700. doi: 10.1212/01.wnl.0000267884.39468.7a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000267884.39468.7a</ArticleId>
            <ArticleId IdType="pubmed">17698793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sussman J, Argov Z, Wirguin Y, et al.  Further developments with antisense treatment for myasthenia gravis. Ann N Y Acad Sci. 2012;1275:13–16. doi: 10.1111/j.1749-6632.2012.06825.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2012.06825.x</ArticleId>
            <ArticleId IdType="pubmed">23278572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Rosenfeld J, Dimachkie MM, et al.  A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of Tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics. 2015;12(2):455–460. doi: 10.1007/s13311-015-0345-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0345-y</ArticleId>
            <ArticleId IdType="pmc">PMC4404445</ArticleId>
            <ArticleId IdType="pubmed">25742919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barth D, Nouri MN, Ng E, et al.  Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017–2023. doi: 10.1212/WNL.0b013e31821e5505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31821e5505</ArticleId>
            <ArticleId IdType="pmc">PMC3109880</ArticleId>
            <ArticleId IdType="pubmed">21562253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bril V, Barnett-Tapia C, Barth D, et al.  IVIg and PLEX in the treatment of myasthenia gravis. Ann N Y Acad Sci. 2012;1275:1–6. doi: 10.1111/j.1749-6632.2012.06767.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2012.06767.x</ArticleId>
            <ArticleId IdType="pubmed">23278570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx A, Pfister F, Schalke B, et al.  Thymus pathology observed in the MGTX trial. Ann N Y Acad Sci. 2012;1275:92–100. doi: 10.1111/j.1749-6632.2012.06799.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2012.06799.x</ArticleId>
            <ArticleId IdType="pubmed">23278583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauriola L, Ranelletti F, Maggiano N, et al.  Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;64(3):536–538. doi: 10.1212/01.WNL.0000150587.71497.B6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000150587.71497.B6</ArticleId>
            <ArticleId IdType="pubmed">15699390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Ströbel P, Jones M, et al.  Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57(3):444–448. doi: 10.1002/ana.20386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20386</ArticleId>
            <ArticleId IdType="pubmed">15732104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saka E, Topcuoglu MA, Akkaya B et al (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65(5):782–783 (author reply 782–3)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16157930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrager JB. Extended transcervical thymectomy: the ultimate minimally invasive approach. Ann Thorac Surg. 2010;89(6):S2128–S2134. doi: 10.1016/j.athoracsur.2010.02.099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.athoracsur.2010.02.099</ArticleId>
            <ArticleId IdType="pubmed">20493996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman RK, Ascioti AJ, van Woerkom JM et al (2011) Long-term follow-up after robotic thymectomy for nonthymomatous myasthenia gravis. Ann Thorac Surg 92(3):1018–1022 (discussion 1022–3)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21871293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marulli G, Schiavon M, Perissinotto E et al (2013) Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis. J Thorac Cardiovasc Surg 145(3):730–735 (discussion 735–6)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23312969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spillane J, Hayward M, Hirsch NP, et al.  Thymectomy: role in the treatment of myasthenia gravis. J Neurol. 2013;260(7):1798–1801. doi: 10.1007/s00415-013-6880-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-6880-8</ArticleId>
            <ArticleId IdType="pubmed">23508539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keijzers M, de Baets M, Hochstenbag M, et al.  Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes. Eur J Cardiothorac Surg. 2015;48(1):40–45. doi: 10.1093/ejcts/ezu352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ejcts/ezu352</ArticleId>
            <ArticleId IdType="pubmed">25234092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rückert JC, Swierzy M, Ismail M. Comparison of robotic and nonrobotic thoracoscopic thymectomy: a cohort study. J Thorac Cardiovasc Surg. 2011;141(3):673–677. doi: 10.1016/j.jtcvs.2010.11.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtcvs.2010.11.042</ArticleId>
            <ArticleId IdType="pubmed">21335125</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
